This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Idexx Laboratories (IDXX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed the most recent trading day at $560.35, moving +0.36% from the previous trading session.
STERIS (STE) Expands Product Suite With New Acquisition
by Zacks Equity Research
STERIS' (STE) acquisition of Cantel Medical will complement and broaden the former's product and service offerings, global reach and customers.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
IDEXX (IDXX) Acquires ezyVet to Boost Practice Management Arm
by Zacks Equity Research
The latest acquisition adds to IDEXX's (IDXX) cloud-based practice information management system (PIMS) segment.
Why Is Idexx (IDXX) Up 3.3% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why IDEXX (IDXX) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider IDEXX (IDXX).
Henry Schein (HSIC) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Henry Schein (HSIC) is optimistic about maintaining robust sales of PPE and COVID-19-related products.
IDEXX (IDXX) Earnings Beat Estimates in Q1, '21 View Up
by Zacks Equity Research
IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.
Idexx Laboratories (IDXX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 36.63% and 5.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Idexx Laboratories (IDXX) Stock Moves -0.66%: What You Should Know
by Zacks Equity Research
In the latest trading session, Idexx Laboratories (IDXX) closed at $548.99, marking a -0.66% move from the previous day.
What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX (IDXX) first-quarter top line is expected to have benefited from strength in CAG and LPD businesses.
Zimmer Biomet (ZBH) Enhances ZBEdge Portfolio With Latest Suite
by Zacks Equity Research
Zimmer Biomet's (ZBH) latest portfolio enhancement is aimed at improving patient outcome throughout the entire treatment process.
Omnicell's (OMCL) 2025 Roadmap Impressive, Pandemic Woe Stays
by Zacks Equity Research
Omnicell (OMCL) expands its autonomous pharmacy portfolio with the acquisition of PSG's 340B Link business.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on its slew of product launches and regulatory approvals.
Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day
COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks
by Urmimala Biswas
We have narrowed down our search to the following stocks, FLGT, BIO and IDXX based on a favorable Zacks Rank and strong prospects for 2021.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) fiscal second-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.
Reasons to Hold on to Syneos Health (SYNH) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery of its operating segments and strategic partnerships.
Here's Why You Should Hold on to Ecolab (ECL) Stock for Now
by Zacks Equity Research
Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness is worrisome.
BD (BDX) Receives FDA EUA for Combination Rapid Antigen Test
by Zacks Equity Research
BD (BDX) gets FDA EUA for new rapid, antigen test, which can distinguish between COVID-19, influenza A and influenza B in a single test.
Zacks Industry Outlook Highlights: Natus Medical, IDEXX Laboratories, Hologic, Thermo Fisher Scientific and Abiomed
by Zacks Equity Research
Zacks Industry Outlook Highlights: Natus Medical, IDEXX Laboratories, Hologic, Thermo Fisher Scientific and Abiomed
Late-Breaking Data Supports Boston Scientific's (BSX) TheraSphere
by Zacks Equity Research
Boston Scientific's (BSX) TheraSphere is expected to be used as a safe and effective treatment option for numerous HCC patients worldwide on the back of positive trial results.
Here's Why You Should Retain Henry Schein (HSIC) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Henry Schein (HSIC) on robust sales of PPE and COVID-19-related products.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to gain traction on a solid product portfolio and strong international exposure. However, stiff competition is worrisome.
OPKO Health (OPK) BioReference Extends COVID-19 School Testing
by Zacks Equity Research
OPKO Health's (OPK) BioReference expands COVID-19 testing in schools to create a safer learning environment for students, teachers, staff and their families.